Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

McMaster University

$135,000.00

Deciphering the metabolic reprogramming of medulloblastoma: novel therapeutic targets and liquid biopsy biomarkers

EF 2022-23

Résumé
Brain tumors are the deadliest childhood cancer. Medulloblastoma (MB) is the most common malignant brain tumor in children, it is a very complex disease with different subgroups (WNT, SHH, Group 3 and Group 4) and subtypes identified. MB can be very aggressive, and despite the therapeutic effort, some patients present a poor prognosis and die from the disease while those that survive suffer from neurocognitive side effects from treatment. For these reasons, the development of new therapies is critical to help patients with MB. Our group has recently discovered that the metabolism of cancer cells in MB is altered when compared to normal developing fetal brain cells. Focusing on MB Group 3 cell lines, we have identified a metabolic vulnerability and developed a pre-clinical strategy with promising results. With this proposal, we aim to characterize the changes in the cancer cell metabolism across the different medulloblastoma subgroups by analyzing patient tumor samples and developing a novel classification system using artificial intelligence. This may allow us to better understand the complexity of this disease and categorize patients based on the metabolic vulnerabilities of their tumors to match them with the most appropriate metabolic therapy. We will also study tumor heterogeneity and evolution at relapse, identify cancer-specific metabolites presented by MB cells through a protein called MR1 and target them with immunotherapies. Moreover, we will develop a less-invasive tool (a liquid biopsy), through the analysis of the fluid around the brain and spine (cerebrospinal fluid), and blood (plasma), that will allow us to identify factors that predict and monitor patient's response to treatment. To complete this project, we are working with our network of collaborators that are experts in the field. Altogether, the ultimate goal will be to translate the discoveries from this project into the clinical setting to help children diagnosed with MB.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
473492
Name
Escudero Laura
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Deciphering the metabolic reprogramming of medulloblastoma: novel therapeutic targets and liquid biopsy biomarkers
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Liquid Biopsies; Medulloblastoma; Metabolic Reprogramming; Pediatric Brain Cancer
Abstract
Brain tumors are the deadliest childhood cancer. Medulloblastoma (MB) is the most common malignant brain tumor in children, it is a very complex disease with different subgroups (WNT, SHH, Group 3 and Group 4) and subtypes identified. MB can be very aggressive, and despite the therapeutic effort, some patients present a poor prognosis and die from the disease while those that survive suffer from neurocognitive side effects from treatment. For these reasons, the development of new therapies is critical to help patients with MB. Our group has recently discovered that the metabolism of cancer cells in MB is altered when compared to normal developing fetal brain cells. Focusing on MB Group 3 cell lines, we have identified a metabolic vulnerability and developed a pre-clinical strategy with promising results. With this proposal, we aim to characterize the changes in the cancer cell metabolism across the different medulloblastoma subgroups by analyzing patient tumor samples and developing a novel classification system using artificial intelligence. This may allow us to better understand the complexity of this disease and categorize patients based on the metabolic vulnerabilities of their tumors to match them with the most appropriate metabolic therapy. We will also study tumor heterogeneity and evolution at relapse, identify cancer-specific metabolites presented by MB cells through a protein called MR1 and target them with immunotherapies. Moreover, we will develop a less-invasive tool (a liquid biopsy), through the analysis of the fluid around the brain and spine (cerebrospinal fluid), and blood (plasma), that will allow us to identify factors that predict and monitor patient's response to treatment. To complete this project, we are working with our network of collaborators that are experts in the field. Altogether, the ultimate goal will be to translate the discoveries from this project into the clinical setting to help children diagnosed with MB.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Escudero, Laura
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~